Zynerba Pharmaceuticals R&D Expenses Reach $5.1M For Q1 2022, Here Are The Details
Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE), reported financial results for the first quarter ended March 31, 2022, revealing net loss of $8.5 million.
Cannabis Co. Kiaro Closes $3.75M Brokered Private Placement
Kiaro Holdings Corp. (TSXV: KO) (OTC: KIARF), a Canadian cannabis retailer and distributor, announced on Wednesday that it has completed a previously announced private placement of 3,759 convertible debenture units at a price of $1,000 per Unit, for gross proceeds of $3.759 million.
Cannabis Unicorn PharmaCann Could IPO Soon, Valued At $1.1B+
One of the largest private cannabis companies in the world could soon go public on the OTC Markets with a valuation of more than $1 billion.